Streamline Health Solutions (STRM) Q2 2025 earnings summary

Executive summary

• Pro forma SaaS revenue grew 21% in the first six months of fiscal 2024, excluding a major client non-renewal from 2023.

• Q2 2024 revenue declined 22% year-over-year to $4.5 million, with net loss widening to $2.8 million.

• SaaS revenue mix increased to 69% of total revenue in Q2 2024, up from 61% in Q2 2023.

• Strategic restructuring in late 2023 reduced expenses, with all related costs recognized by July 31, 2024.

• Management remains focused on product innovation, AI-driven enhancements, and expanding client footprint.

Financial highlights

• Q2 2024 total revenue was $4.5 million, down from $5.8 million in Q2 2023; six-month revenue was $8.8 million, down from $11.1 million year-over-year.

• Adjusted EBITDA loss improved to $0.3 million in Q2 2024 from $0.9 million in Q2 2023.

• Q2 2024 net loss was $2.8 million ($0.05/share), compared to $2.5 million ($0.04/share) in Q2 2023.

• Operating expense for Q2 2024 was $6.7 million, down from $8.4 million in Q2 2023.

• Cash and cash equivalents as of July 31, 2024, were $3.5 million, up from $3.2 million at January 31, 2024.

Outlook and guidance

• Adjusted EBITDA breakeven run rate of $15.5 million implemented SaaS ARR now expected in the second half of fiscal 2025.

• Revenue is expected to remain relatively flat for the remainder of fiscal 2024, with growth anticipated in fiscal 2025.

• Management expects more than double first-half bookings in the second half of fiscal 2024.

• The company projects potential non-compliance with certain financial covenants in the next twelve months, raising substantial doubt about its ability to continue as a going concern.